Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 33

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 15
Chunk 33
---
 202410-Q001-3779810.3(b)5/8/202410.11(c)†Second Amendment to Lease Agreement by and between 7495 RP, LLC and the Registrant dated August 30, 202410-Q001-3779810.111/7/202410.12#Employment Agreement, dated as of September 25, 2018, by and between the Registrant and Carsten Brunn, Ph.D.8-K001-3779810.29/27/201810.13#Employment Agreement, dated as of November 9, 2022, by and between the Registrant and Blaine Davis10-K001-3779810.153/2/202310.14#Employment Agreement, dates as of March 26, 2024, by and between the Registrant and Christopher Jewell, Ph.D.8-K001-3779810.14/1/202410.15#Employment Agreement, dates as of March 28, 2024, by and between the Registrant and Metin Kurtoglu, M.D., Ph.D.8-K001-3779810.24/1/2024

73

Table of Contents

10.16(a)†License and Development Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)10-Q001-3779810.28/6/202010.16(b)†Amendment No. 1 to License and Development Agreement, dated as of October 31, 2023, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)10-K001-3779810.15(b)3/7/202410.17†Patent License Agreement, between Cartesian Therapeutics, Inc. and the U.S. Department of Health and Human Services, as represented by the National Cancer Institute of the National Institutes of Health, dated September 16, 201910-K001-3779810.163/7/202410.18†Patent License Agreement by and between Biogen MA, Inc. and Cartesian Therapeutics, Inc., dated September 8, 202310-K001-3779810.173/7/202410.19#Form of Retention Bonus Letter8-K001-3779810.311/13/202310.20Securities Purchase Agreement, dated as of